1492 Capital Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

1492 Capital Management’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-118,225	Closed	-$13.5M	–	122
2022 Q4	$13.5M	Sell	118,225 -1,611	-1%	-$134K	8.67%	1
2022 Q3	$7.42M	Sell	119,836 -254	-0.2%	-$17.7K	5.34%	1
2022 Q2	$9.58M	Sell	120,090 -1,750	-1%	-$166K	6.3%	1
2022 Q1	$12.8M	Buy	121,840 +1,845	+2%	+$180K	6.8%	1
2021 Q4	$12.9M	Buy	119,995 +834	+0.7%	+$91K	6.37%	1
2021 Q3	$13.1M	Sell	119,161 -365	-0.3%	-$37.9K	6.6%	1
2021 Q2	$11.2M	Buy	119,526 +815	+0.7%	+$75K	5.72%	1
2021 Q1	$10.9M	Sell	118,711 -18,243	-13%	-$1.54M	6.22%	1
2020 Q4	$10M	Sell	136,954 -20,040	-13%	-$1.49M	5.77%	1
2020 Q3	$12.2M	Sell	156,994 -10,934	-7%	-$752K	9.13%	1
2020 Q2	$9.33M	Sell	167,928 -13,240	-7%	-$566K	7.99%	2
2020 Q1	$5.37M	Sell	181,168 -1,886	-1%	-$63.8K	6.42%	2
2019 Q4	$6.63M	Buy	183,054 +11,433	+7%	+$351K	5.86%	1
2019 Q3	$4.67M	Buy	+171,621	New	+$4.44M	4.56%	3
2019 Q2	–	Sell	-193,063	Closed	-$5.1M	–	106
2019 Q1	$5.1M	Sell	193,063 -20,297	-10%	-$481K	4.32%	3
2018 Q4	$4.17M	Buy	213,360 +74,047	+53%	+$1.45M	3.74%	4
2018 Q3	$2.73M	Buy	139,313 +66,362	+91%	+$1.26M	1.78%	19
2018 Q2	$1.21M	Buy	72,951 +26,076	+56%	+$398K	0.86%	42
2018 Q1	$666K	Buy	+46,875	New	+$692K	0.51%	61

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DKCM

Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

1492 Capital Management's HZNP Position: Q1 2023 in Review

1492 Capital Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q1 2023, closing a stake of 118,225 shares — an estimated $13.5M sold.

1492 Capital Management first reported a position in HZNP in Q1 2018 and held it in 19 quarters. The position peaked at $13.5M in Q4 2022. 553 funds tracked by Wall St. Rank hold HZNP as of Q1 2023.

1492 Capital Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q1 2023 after selling out during the quarter.
1492 Capital Management sold 118,225 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q1 2023, an estimated $13.5M.
1492 Capital Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2018 and held it in 19 quarters.
1492 Capital Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $13.5M in Q4 2022.
553 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q1 2023.

Based on 1492 Capital Management's 13F filing for Q1 2023, filed 12 May 2023.